Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

ABSTRACT:

SUBMITTER: Nishio M 

PROVIDER: S-EPMC12127625 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature